GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Piotroski F-Score
中文

Precision BioSciences (Precision BioSciences) Piotroski F-Score : 3 (As of Apr. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Precision BioSciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Precision BioSciences's Piotroski F-Score or its related term are showing as below:

DTIL' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 7 years, the highest Piotroski F-Score of Precision BioSciences was 5. The lowest was 1. And the median was 3.


Precision BioSciences Piotroski F-Score Historical Data

The historical data trend for Precision BioSciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Piotroski F-Score Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial 3.00 2.00 5.00 1.00 3.00

Precision BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 3.00 3.00 3.00

Competitive Comparison of Precision BioSciences's Piotroski F-Score

For the Biotechnology subindustry, Precision BioSciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -25.06 + -11.891 + -8.079 + -16.289 = $-61.32 Mil.
Cash Flow from Operations was -31.464 + -21.134 + -23.093 + -8.423 = $-84.11 Mil.
Revenue was 8.78 + 19.789 + 13.12 + 7.038 = $48.73 Mil.
Gross Profit was 8.78 + 19.789 + 13.12 + 7.038 = $48.73 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(238.169 + 204.502 + 181.697 + 164.344 + 159.781) / 5 = $189.6986 Mil.
Total Assets at the begining of this year (Dec22) was $238.17 Mil.
Long-Term Debt & Capital Lease Obligation was $7.72 Mil.
Total Current Assets was $136.36 Mil.
Total Current Liabilities was $49.99 Mil.
Net Income was -28.168 + -31.035 + -23.946 + -28.488 = $-111.64 Mil.

Revenue was 3.317 + 3.82 + 7.363 + 10.598 = $25.10 Mil.
Gross Profit was 3.317 + 3.82 + 7.363 + 10.598 = $25.10 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(211.498 + 181.351 + 297.163 + 271.733 + 238.169) / 5 = $239.9828 Mil.
Total Assets at the begining of last year (Dec21) was $211.50 Mil.
Long-Term Debt & Capital Lease Obligation was $23.28 Mil.
Total Current Assets was $199.11 Mil.
Total Current Liabilities was $59.66 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Precision BioSciences's current Net Income (TTM) was -61.32. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Precision BioSciences's current Cash Flow from Operations (TTM) was -84.11. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-61.319/238.169
=-0.25746004

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-111.637/211.498
=-0.52783951

Precision BioSciences's return on assets of this year was -0.25746004. Precision BioSciences's return on assets of last year was -0.52783951. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Precision BioSciences's current Net Income (TTM) was -61.32. Precision BioSciences's current Cash Flow from Operations (TTM) was -84.11. ==> -84.11 <= -61.32 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=7.723/189.6986
=0.04071195

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=23.282/239.9828
=0.09701529

Precision BioSciences's gearing of this year was 0.04071195. Precision BioSciences's gearing of last year was 0.09701529. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=136.359/49.987
=2.72788925

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=199.105/59.664
=3.33710445

Precision BioSciences's current ratio of this year was 2.72788925. Precision BioSciences's current ratio of last year was 3.33710445. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Precision BioSciences's number of shares in issue this year was 4.164. Precision BioSciences's number of shares in issue last year was 3.699. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=48.727/48.727
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=25.098/25.098
=1

Precision BioSciences's gross margin of this year was 1. Precision BioSciences's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=48.727/238.169
=0.20459002

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=25.098/211.498
=0.11866779

Precision BioSciences's asset turnover of this year was 0.20459002. Precision BioSciences's asset turnover of last year was 0.11866779. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Precision BioSciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Precision BioSciences  (NAS:DTIL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Precision BioSciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701